Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Adaptive Biotechnologies is a commercial-stage biotech company specializing in immune-driven medicine through its proprietary immune medicine platform (immunoSEQ) that sequences T-cell and B-cell receptors. The company operates two primary businesses: a clinical diagnostics franchise focused on minimal residual disease (MRD) testing in blood cancers (clonoSEQ, FDA-cleared), and a drug discovery partnership with Genentech developing T-cell receptor-based therapeutics. With 74% gross margins but negative operating margins, ADPT is in the classic biotech growth-to-profitability transition phase, burning cash to scale commercial operations and R&D.
ADPT monetizes its proprietary T-cell and B-cell receptor sequencing technology through three channels: (1) Direct clinical revenue from clonoSEQ, a FDA-cleared MRD test reimbursed by Medicare/commercial payers at approximately $2,800-3,200 per test, with minimal marginal costs after sequencing infrastructure investment; (2) Multi-year collaboration agreements with pharma partners (notably Genentech's $300M+ deal structure) providing upfront payments, research funding, milestones, and future royalties on approved therapeutics; (3) Research service fees from academic institutions and biopharma conducting immune repertoire studies. Competitive advantages include first-mover status in FDA-cleared MRD testing, proprietary algorithms for analyzing billions of immune receptor sequences, and exclusive access to the world's largest immune repertoire database. Pricing power in diagnostics is constrained by payer reimbursement rates but protected by regulatory clearance barriers.
clonoSEQ test volume growth and Medicare/commercial payer adoption rates in multiple myeloma, ALL, and CLL indications
Genentech collaboration progress updates including IND filings, clinical trial initiations, and milestone payment triggers for TCR-based therapeutics
FDA regulatory expansions for clonoSEQ into new cancer types (solid tumors represent significant TAM expansion opportunity)
Quarterly cash burn rate and pathway to profitability guidance, particularly operating expense leverage as revenue scales
New pharma partnerships or platform licensing deals that validate the immune medicine technology beyond Genentech
Reimbursement policy changes from CMS or commercial payers could compress clonoSEQ pricing; Medicare coverage decisions are binary events that significantly impact addressable market and unit economics
Competitive MRD testing technologies (liquid biopsy, ctDNA-based approaches from Guardant, Natera) may offer alternative solutions with different performance characteristics, fragmenting the MRD market before ADPT achieves dominant scale
Regulatory pathway uncertainty for expanding clonoSEQ into solid tumors where immune repertoire biology is less established than hematologic malignancies
Large diagnostics incumbents (Roche, Illumina) could leverage sequencing cost advantages and distribution scale to enter MRD testing if market proves attractive
Pharma partners developing internal immune profiling capabilities could reduce dependence on ADPT's platform for future drug discovery programs
Academic institutions and competitors building alternative immune repertoire databases could erode ADPT's proprietary data moat over 5-10 year horizon
Cash burn of approximately $100M annually requires either achieving profitability by 2027-2028 or accessing capital markets; equity dilution risk exists if growth disappoints and additional financing needed at unfavorable valuations
Debt/Equity of 1.28x is manageable but represents convertible notes that could dilute shareholders if stock price appreciates significantly; conversion terms and maturity schedule create overhang
Negative ROE of -30% reflects accumulated losses; path to positive returns depends on successful commercial execution and collaboration milestone achievements
low - Clinical diagnostics for cancer patients are non-discretionary medical services with minimal GDP sensitivity; oncologists order MRD tests based on clinical guidelines rather than economic conditions. However, pharma R&D budgets (affecting collaboration revenue) exhibit moderate cyclical sensitivity during severe recessions when biotech funding contracts. The 54% revenue growth rate reflects commercial launch dynamics rather than economic cycle positioning.
Rising interest rates create moderate headwinds through two channels: (1) Higher discount rates compress valuation multiples for pre-profitable biotech stocks (ADPT trades at 8.6x sales, sensitive to risk-free rate changes); (2) Tighter financial conditions reduce biotech sector funding availability, potentially impacting future partnership economics and capital raising ability. However, the company's $400M+ cash position (implied by 3.34x current ratio) and declining cash burn provide 3-4 year runway, reducing near-term financing pressure. Rate impacts are primarily valuation-driven rather than operational.
Minimal direct credit exposure. The business model does not rely on consumer or corporate credit availability. Reimbursement from Medicare and commercial insurers represents low credit risk. Indirect exposure exists through pharma partner financial health (Genentech/Roche is investment-grade, minimal concern) and biotech sector access to capital markets for future partnerships, but this is secondary to core operations.
growth - The stock attracts growth investors focused on commercial-stage biotech with platform technology potential, evidenced by 89% one-year return and 8.6x sales valuation. Investors are underwriting rapid revenue scaling (55% YoY growth), pathway to profitability within 2-3 years, and optionality from pharma partnerships generating milestone/royalty streams. The negative cash flow and high P/S multiple indicate this is not a value or income play; momentum investors have driven recent outperformance as MRD testing adoption accelerates. Institutional biotech specialists and healthcare-focused growth funds represent core holder base.
high - As a $2.4B market cap, pre-profitable biotech with binary clinical/regulatory catalysts, ADPT exhibits elevated volatility typical of the sector. Stock moves 5-15% on earnings reports, partnership announcements, and FDA regulatory updates. Beta likely exceeds 1.3-1.5x relative to broader market. The 89% one-year return followed by 14% three-month return demonstrates momentum-driven trading patterns. Volatility will remain elevated until the company achieves consistent profitability and reduces dependence on lumpy collaboration milestone revenue.
